A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

The study is intended to focus on diagnostics and treatment of Lyme IACI symptoms and not to improve diagnostics and treatment for acute Lyme disease. As such, the prevention of Lyme disease ...

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

Cohen, E. and Kubinak, N. (2025) A Rare Presentation of Cavernous Sinus Thrombosis in a Young Female. Surgical Science, 16, ...

In fact, treatment might need to be started even if the diagnosis of APL is suspected but hasn't been confirmed yet by lab tests. APL treatment differs from the treatment of most other types of AML.

Over a hundred sickle cell warriors and their families turned out in support for World Sickle Cell Day at West Oakland’s ...

Several other medical conditions can mimic the symptoms of low testosterone, including depression, sleep apnea, ...

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

Learn more about myocardial ischemia, which is often caused by severe anemia and results in a disruption of blood flow to the ...

Anemia is a common condition and has many causes, one of which is hemolytic disease of the fetus and newborn (HDFN), a ...

New findings reveal that combining erythropoiesis-stimulating agents with ruxolitinib maintains efficacy in treating ...